Shyu Charles, Burke Kelly, Souweidane Mark M, Dunkel Ira J, Gilheeney Stephen W, Gershon Timothy, Khakoo Yasmin
Department of Neurology, University of Illinois at Urban-Champaign, New York, NY 10065, USA.
J Pediatr Hematol Oncol. 2011 Mar;33(2):148-9. doi: 10.1097/MPH.0b013e3182053a1a.
Cerebellar mutism syndrome (CMS) is a complication of posterior fossa surgery seen primarily in pediatric patients after resection of medulloblastoma. CMS is characterized by mutism, ataxia, hypotonia, and irritability. Currently, there is no therapy of proven efficacy. Zolpidem, although primarily used as a sedative, has been shown to alleviate mutism and promote arousal in similar neurologic and psychiatric disorders. Here, we describe a child with severe CMS in whom zolpidem seemed to increase arousal, accelerate the resolution of mutism, and decrease emotional lability. Our report suggests that clinicians should consider using zolpidem for patients with CMS.
小脑缄默综合征（CMS）是后颅窝手术的一种并发症，主要见于小儿髓母细胞瘤切除术后。CMS的特征为缄默、共济失调、肌张力减退和易激惹。目前，尚无经证实有效的治疗方法。唑吡坦虽主要用作镇静剂，但已显示在类似的神经和精神疾病中可减轻缄默并促进觉醒。在此，我们描述一名患有严重CMS的儿童，唑吡坦似乎可提高其觉醒水平、加速缄默的缓解并减少情绪不稳定。我们的报告提示临床医生应考虑对CMS患者使用唑吡坦。
